

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of: **David Brayden**

Application No.: **09/386,709**

Filed: **August 31, 1999**

For: **ORAL VACCINE COMPOSITIONS**

Attorney Docket No. **P26,488-A USA**



Examiner: **J. E. Graser**

Group Art Unit: **1645**

1645  
P#29  
**RECEIVED**  
FEB 24 2003  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence, along with any paper indicated as being enclosed, are being sent via First Class Mail addressed to: Commissioner for Patents, Washington, D.C. 20231, on February 14, 2003.

2/14/03  
Date

Andrea C. Wright  
Andrea C. Wright

Commissioner for Patents  
Washington, DC 20231

**SUPPLEMENTAL INFORMATION DISCLOSURE**  
**STATEMENT PURSUANT TO 37 C.F.R. §§ 1.17(p) and 1.97(e)**

Dear Sir:

It is respectfully requested that the publications listed on the enclosed Form PTO-1449 be made of record and considered with respect to the above-referenced U.S. Patent Application. A copy of each publication is enclosed. Submission of the present Supplemental Information Disclosure Statement should not be taken as an admission that the cited publications are legally available prior art or that the same are pertinent or material.

The Commissioner is authorized to charge applicant's Deposit Account No. 19-5425 for any charges in connection with this Supplemental Information Disclosure Statement.

Respectfully submitted,

Feb. 14, 2003  
Dated

Patrick J. Kelly  
Patrick J. Kelly  
Registration No. 34,638

SYNNESTVEDT & LECHNER LLP  
2600 ARAMARK Tower  
1101 Market Street  
Philadelphia, PA 19107-2950  
Telephone: (215) 923-4466  
Facsimile: (215) 923-2189

(Use several sheets if necessary)

P26,488-A U.S.A.

**09/386,709**

**Applicant(s)**

## David Brayden

**Filing Date**

**August 31, 1999**

### Group Art Unit

1645

FEB 20 2003

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	Robert Brey Ph.D. et al., "Oral Administration of Tetanus Vaccine", PMCI, PharmaMedical Consultants International, Issues related to acceptance, target populations and clinical trials, pages 1/11
AD	Steven L. Regen, "Liposomes", From Biophysics to Therapeutics, edited by Marc J. Ostro, The Liposome Company, Marcel Dekker, Inc., New York and Basel, pages 73-108

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FEB 20 2003

Docket Number (Optional)

P26,488-A USA

Application Number

09/386,709

Applicant(s)

David Brayden

Filing Date

August 31, 1999

Group Art Unit

1645

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AE

D.S. Johnston, et al., "Preparation of Liposomes", Liposome Technology, Volume I, pages 123-129

AF

Catherine Ferreccio, et al., "The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age", The Pediatric Infectious Disease Journal, Vol. 10, No. 10, October 1991, pages 764-771

AG

John D. Clemens, et al., "Impact of Haemophilus influenzae Type b Polysaccharide-Tetanus Protein Conjugate Vaccine on Responses to Concurrently Administered Diphtheria-Tetanus-Pertussis Vaccine", JAMA, February 5, 1992, Vol. 267, No. 5, pages 673-678

AH

Kingston H. G. Mills, et al., "Cell-Mediated Immunity to Bordetella pertussis: Role of Th1 Cells in Bacterial Clearance in a Murine Respiratory Infection Model", Infection and Immunity, February 1993, Vol. 61, No. 2, pages 399-410

AI

K. J. Maloy, et al., "Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles", Immunology, 1994, Vol. 81, pages 661-667

AJ

Edwin L. Anderson, et al., "Acellular pertussis vaccines in infants: evaluation of single component and two-component products", Center for Vaccine Development, Division of Infectious Diseases, March 19, 1993, 4 pages

AK

Werner Rubas, et al., "An Integrated Method to Determine Epithelial Transport and Bioactivity of Oral Drug Candidates in Vitro", Pharmaceutical Research, Vol. 13, No. 1, 1996, pages 23-26

AL

Roberta Shahin, et al., "Adjuvanticity and Protective Immunity Elicited by Bordetella pertussis Antigens Encapsulated in Poly(DL-Lactide-Co-Glycolide) Microspheres", Infection and Immunity, April 1995, Vol. 63, No. 4, pages 1195-1200

AM

J. Terry Ulrich, et al., "Monophosphoryl Lipid A as an Adjuvant, Past Experiences and New Directions", Chapter 21, pages 495-522

AN

E.S. Cahill, et al., "Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles", Vaccine, 1995, Vol. 13, No. 5, pages 455-462

AO

Anne Morre, et al., "Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells", Vaccine, October 29, 1995, Vol. 18, pages 1-11

AP

Ying Men, et al., "A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide", Vaccine, Vol. 13, No. 7, pages 683-689

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FEB 20 2003

Docket Number (Optional)

P26,488-A USA

Application Number

09/386,709

Applicant(s)

David Brayden

Filing Date

August 31, 1999

Group Art Unit

1645

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ

Manisha P. Desai et al., "Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size", Pharmaceutical Research, Vol. 13, No. 12, 1996, pages 1838-1841

AR

K. D. Newman et al., "Ovalbumin peptide encapsulated in Poly(D,L lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response", Journal of Controlled Release, 54, 1998, pages 49-59

AS

Siobhan McClean et al., "Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia", European Journal of Pharmaceutical Sciences, 1997, 3 pages

AT

MA Coyle et al., "In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine", Gene Therapy, 1998, Vol. 5, pages 645-651

AU

M. Ryan et al., "Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children", Immunology, Vol. 93, 1998, pages 1-10

AV

J. Nugent et al., "Design and delivery of non-parenteral vaccines", Journal of Clinical Pharmacy and Therapeutics, Vol. 23, 1998, pages 257-285

AW

Graham A. W. Rook et al., "Give us this day our daily germs", View Point - Immunology Today, Vol. 19, No. 3, March 1998, pages 113-120

AX

Kimberley D. Newman et al., "Delivery of MUC1 Mucin Peptide by Poly(D,L-lactic-co-glycolic acid) Microspheres Induces Type 1 T Helper Immune Responses", Journal of Pharmaceutical Sciences, Vol. 87, No. 11, November 1998, pages 1421-1427

AY

Harokopakis et al., "Effectiveness of Liposomes Possessing Surface-Linked Recombinant B Subunit of Cholera Toxin as an Oral Antigen Delivery System", Vaccine Delivery, page 20, 2nd paragraph

AZ

David J. Brayden et al., "Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines", PSTT, Vol. 1, No. 7, October 1998, pages 291-298

BA

Jeffrey L. Cleland, "Single-administration vaccines: controlled-release technology to mimic repeated immunizations", TIBTECH, January 1999, Vol. 17, pages 25-29

BB

Maria Tobio et al., "A Novel System Based on a Poloxamer/PLGA Blend as a Tetanus Toxoid Delivery Vehicle", Pharmaceutical Research, Vol. 16, No. 5, 1999, pages 682-688

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FEB 20 2003

Docket Number (Optional)

P26,488-A USA

Application Number

09/386,709

Applicant(s)

David Brayden

Filing Date

August 31, 1999

Group Art Unit

1645

\*EXAMINER  
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BC

Khushroo E. Shroff et al., "Potential for plasmid DNAs as vaccines for the new millennium", PSTT, Vol. 2, No. 5, May 1999, pages 205-213

BD

Prosper N. Boyaka et al., "IL-12 Is an Effective Adjuvant for Induction of Mucosal Immunity", The Journal of Immunology, 1999, pages 122-128

BE

Mariarosaria Marinaro et al., "Use of Intranasal IL-12 to Target Predominantly Th1 Responses to Nasal and Th2 Responses to Oral Vaccines Given with Cholera Toxin", The Journal of Immunology, 1999, pages 114-121

RECEIVED

FEB 24 2003

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.